William Blair Reiterates Outperform Rating on Denali Therapeutics Inc. (DNLI) 'Remains undervalued and de-risked'

July 7, 2025 10:45 AM EDT Send to a Friend
William Blair analyst Myles Minter reiterated an Outperform rating on Denali Therapeutics Inc. (NASDAQ: DNLI)The analyst commented, "Today’s BLA acceptance ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login